<DOC>
	<DOCNO>NCT01266876</DOCNO>
	<brief_summary>The purpose study assess efficacy safety REGN727/SAR236553 participant diagnose heterozygous familial hypercholesterolemia ( heFH )</brief_summary>
	<brief_title>Study Safety Efficacy REGN727/SAR236553 Patients With HeFH Hypercholesterolemia</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Must meet World Health Organization criterion heFH 2 . Participants must stable statin dose , without ezetimibe , least 6 week screen 3 . Serum LDLC level ≥ 100 mg/dL screen 4 . Willing follow NCEP ATPIII TLC diet , equivalent diet plan , start screen continue last study visit 5 . A negative urine/serum pregnancy test screen visit start study , woman childbearing potential Key 1 . Participants homozygous FH ( clinically previous genotyping ) 2 . Use medication ( statin EZE ) alter serum lipid within 42 day ( 6 week ) screen include , limited : Fibrates Niacin ( &gt; 500 mg/day ) Omega3 fatty acid ( &gt; 1000 mg/day DHA/EPA ) Bile acid resins 3 . Use nutraceuticals OTC medication may alter lipid level stable least 6 week screen plan remain constant throughout study . Examples include : Omega3 fatty acid ( ≤1000 mg/day DHA/EPA ) Niacin ( ≤500 mg/day ) Plant stanols , find Benecol , flax seed oil , psyllium Red yeast rice 4 . Disorders know influence lipid level , nephrotic syndrome , significant liver disease , Cushing 's disease , untreated hypothyroidism ( patient stable thyroid replacement least 12 week full screen visit , metabolically euthyroid thyroidstimulating hormone ( TSH ) test allow ) 5 . Use thyroid medication ( except replacement therapy stable least 12 week full screen visit ) 6 . Fasting serum TG &gt; 350 mg/dL screen 7 . LDL apheresis within 12 month screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>